TrialTrials2023

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.

Sonia Jaramillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.